ProCE Banner Activity

Phase II SWOG S1929: Maintenance Atezolizumab ± Talazoparib for SLFN11-Positive Extensive-Stage SCLC

Conference Coverage
Slideset

The addition of talazoparib to atezolizumab maintenance therapy improved PFS in patients with SLFN11-positive extensive-stage SCLC.

Released: June 09, 2023

Share

Provided by

Provided by Clinical Care Options, LLC

ProCE Banner

Supporters

Supported by educational grants from AstraZeneca, Daiichi Sankyo, Merck Sharp & Dohme Corp., and Novocure.

AstraZeneca

Daiichi Sankyo

Merck Sharp & Dohme Corp.

Novocure